{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-007394","form_type":"8-K","ticker":"ZEOX","cik":"0001557376","company_name":"Zeo ScientifiX, Inc.","filed_at":"2026-07-08T12:00:28+00:00","discovered_at":"2026-07-08T12:05:00.259038+00:00","generated_at":"2026-07-08T12:05:13.708058+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zeo ScientifiX Q1 FY2026 revenue up 124.6% to $2.58M; net loss narrows to ~$1.0M","bullets":["Revenue for quarter ended Apr 30, 2026: $2.58M vs $1.15M a year ago, +124.6%.","Six-month revenue: $4.03M vs $2.24M, +79.9%, driven by allogenic biologic products.","Gross margins maintained at ~80% for both six-month periods.","Net loss for six months reduced to ~$1.0M from ~$2.6M in prior-year period.","CEO cites growing physician adoption and commercial momentum in Florida."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-007394","json":"https://secwatch.observer/filing/0001829126-26-007394.json","markdown":"https://secwatch.observer/filing/0001829126-26-007394.md","text":"https://secwatch.observer/filing/0001829126-26-007394.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557376/000182912626007394/0001829126-26-007394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557376/000182912626007394/zeoscientifix_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-08T12:05:13.708058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}